Sorafenib and Bevacizumab in Treating Patients With Refractory, Metastatic, or Unresectable Solid Tumors - Related Studies

Sorafenib and Bevacizumab in Treating Patients With Refractory, Metastatic, or Unresectable Solid Tumors

This study is ongoing, but not recruiting participants.

Study NCT00098592. Last updated on October 18, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Cancer

2	Interventions listed in this trial
		bevacizumab
		sorafenib tosylate

3	Additional drug interventions recognized in this trial
		Sorafenib

4	More general drug interventions related to this trial
		Angiogenesis Inhibitors
		Angiogenesis Modulating Agents
		Antineoplastic Agents
		Enzyme Inhibitors
		Growth Inhibitors
		Growth Substances
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Physiological Effects of Drugs
		Protein Kinase Inhibitors
		Therapeutic Uses

5	Sponsors listed in this trial
		NCI - Center for Cancer Research-Medical Oncology
		National Cancer Institute (NCI)